Press Release
TOKYO DOME CITY

TOKYO DOME CORPORATION
さあ、街から未来をかえよう
三井不動産グループ
MITSUI FUDOSAN GROUP

May 13, 2026

TOKYO DOME CORPORATION

[Event Report]
“Japan–U.S ALS Forum” Hosted by Tokyo Dome Corporation
— Creating the Future Through Diverse Voices: Where Hope Meets Innovation —

Tokyo Dome Corporation (Head Office: Bunkyo-city, Tokyo; Representative Director: Yutaka Saito) held “Japan–U.S. ALS Forum” on Tuesday, March 31, 2026, at the Tokyo Dome Hotel. The forum brought together knowledge and expertise from Japan and the United States with the aim of advancing efforts toward a cure for ALS (Amyotrophic Lateral Sclerosis). With the completion of the official video documenting the event, we are pleased to provide the event highlights.

Approximately 130 invited guests, including people living with ALS, their family members, supporters, and researchers, attended the forum. The program featured presentations on the latest regenerative cell therapy research by Regelife, Inc. (U.S.), as well as panel discussions with specialists from Japan and the United States. Through these sessions, the forum deepened dialogue focused on the future, grounded in the diverse voices and perspectives of those directly affected by ALS. In consideration of diverse communication needs, including eye-tracking input and other assistive communication methods, the forum utilized advanced question submissions and same-day survey systems. In addition, the venue was equipped with power supplies for suction devices and dedicated care spaces, creating an environment that enabled participants in a wide range of circumstances to engage proactively and independently.

Official Movie URL： https://youtu.be/ZbxOtBQFUv4
Digest Movie URL： https://youtu.be/zA2sBj2fq5Q

Background of the Event

Guided by its corporate philosophy of “sharing “heart-moving” experiences,” Tokyo Dome Corporation has created a wide range of leisure and entertainment experiences while striving to contribute to a more enriching society. As a company dedicated to providing enjoyment and purpose in life, we sought to create a place where hope and innovation meet, and to contemplate the future together with people living with ALS and their families. It was this strong commitment that led to the hosting of this forum. By sharing cutting-edge scientific knowledge, the forum also aimed to contribute to the realization of a society in which the thoughts and hopes of each individual are respected.

Event Overview

Event Name: Japan–U.S. ALS Forum
Date: Tuesday, March 31, 2026
Venue: “Cynthia,” B1, Tokyo Dome Hotel
Organizer: Tokyo Dome Corporation
Sponsors / Partners: ALS Network
Keio University Regenerative Medicine Research Center
Regelife
WITH ALS (General Incorporated Association)
LIBRA Co., Ltd.
ALS/MND Support Center Sakura-kai (Specified Nonprofit Organization)
Future of Humanity Institute
Serika Fund (General Incorporated Association)
Takanowa LLC
Japan ALS Association (General Incorporated Association)
Yoshimoto Kogyo Holdings Co., Ltd.
END ALS (General Incorporated Association)
LINK-J (General Incorporated Association)
Speakers: Hideyuki Okano (Director and Professor,
Keio University Regenerative Medicine Research Center)
Sheri Strahl (President & CEO, ALS Network; MPH, MBA)
Mark Ma (CEO & Co-Founder, Regelife)
Masatane Muto (Representative Director, WITH ALS)
Attendance: Approximately 130 participants

Highlights and Key Content of the Forum

1. Presentations on the Latest Developments in Japan–U.S. ALS Support and Technology

Sheri Strahl, who is actively engaged on the front lines of ALS support in the United States, and Masatane Muto, an individual living with ALS who works as a communication creator using technologies such as eye-tracking input to promote expression and raise awareness of ALS, took the stage as speakers.

[Presentation by Sheri Strahl]

Sheri spoke about what she described as “three positive shifts” in the current ALS landscape. These included the evolution of care through multidisciplinary clinical teams; the emergence of strong partnerships between patients and researchers, in which patients themselves lead new discoveries and participate in the design of clinical trials; and the remarkable acceleration of science driven by the use of AI and biomarkers. She emphasized that when these three forces come together, they open pathways toward meaningful treatments and ultimately a cure. Concluding her presentation, she delivered a powerful message: “We now have real and compelling reasons to hold genuine hope.”

[Presentation by Masatane Muto]

Masatane Muto, who is himself living with ALS and continues to work internationally as a creator, spoke about the future of ALS being shaped by technology and art from the perspective of “NO LIMIT, YOUR LIFE”—a philosophy of living without self-imposed limitations. Drawing on his own experience, he introduced examples of cutting-edge technologies that extend lost physical functions and enable continued connection with society, including devices utilizing eye-tracking and brainwave input, as well as avatar and telepresence robots.

2. Panel Discussion Featuring Key Figures from Japan and the United States, and Dialogue Where Diverse Voices Intersect

In the first half of the session, Hideyuki Okano, a leading figure in regenerative medicine in Japan, and Mark Ma, who is engaged in regenerative medicine research aimed at achieving a cure for ALS, took the stage.

[Presentation by Mark Ma]

At the beginning of the panel discussion, Mark presented his latest research under the theme of “Rebuilding Neural Connectivity in ALS.” He introduced research outcomes that combine advanced cell therapies with microenvironment engineering. While many current ALS treatments focus primarily on slowing disease progression, Mark presented a vision centered on restoring and reconstructing lost neural functions. Specifically, he explained an approach in which healthy motor neurons are generated from a patient’s own cells using iPS cell technology and then transplanted into the body. He also addressed the challenge that the bodies of ALS patients often present a harsh microenvironment in which transplanted cells struggle to survive due to inflammation and other factors. To overcome this, he outlined an innovative mechanism in which AI is used to design and deliver biomaterials (hydrogels) that support the survival and engraftment of transplanted cells.

[Panel Discussion (First Half)]

In the discussion that followed the presentations, Professor Okano stated, “To ensure that science and technology truly benefit society, perspectives beyond research alone—such as business and industrialization—are essential,” underscoring the importance of simultaneous development in Japan and the United States. The discussion highlighted that leading researchers and organizations from both countries are working collaboratively, demonstrating that a strong and increasingly robust framework for Japan–U.S. cooperation is being built.

[Panel Discussion (Second Half) and Q&A Session]

In the second half of the panel discussion, Sheri Strahl, Mark Ma, and Masatane Muto exchanged views on the current state and future of support systems in Japan and the United States. The discussion covered prospects for cutting-edge communication technologies utilizing brain–machine interfaces (BMIs) and AI, the importance of early-stage care through multidisciplinary collaboration, and more in-depth perspectives, such as expectations for the speed of Japan's regulatory authorities (PMDA) in accelerating clinical trials.

A Q&A session with attendees was also held, during which discussions extended beyond expectations for treatment development to include daily life and the perspectives of families. Through open dialogue with the speakers, these conversations were further deepened. Participants living with ALS, supporters, and researchers came together across boundaries to share a strong collective determination: for Japan and the United States to unite as one team in realizing a future where ALS can be cured as soon as possible—even one day sooner.

3. NFT (Non-Fungible Token) Giveaway as a "Proof of Hope"

Toward the conclusion of the event, a non-transferable NFT (non-fungible token) created by the Company was distributed to attendees as a symbol of the bonds shared by members of the community united in the pursuit of a cure for ALS. With the intention of creating a lasting "proof of participation"—allowing participants to later reflect on having taken part, having connected, and having supported one another—the NFT was designed by Masatane Muto, who also appeared as a speaker at the forum.



Please view the official video introduced at the beginning to see highlights from the forum.

Handling of Medical Information and Research Status Presented at the Forum

*The research presented at this event regarding efforts by Regelife, Inc. (U.S.) to achieve a fundamental cure for ALS using iPS cells, as well as the outlook for regulatory approval by the U.S. Food and Drug Administration (FDA) is based on the company's current research progress and plans. These initiatives are still in the research stage and do not guarantee specific therapeutic outcomes at this time.

*Tokyo Dome Corporation, as the organizer, held this event intending to provide a platform for collaboration among people living with ALS, supporters, and researchers in Japan and the United States.

*The presented materials do not guarantee the accuracy, completeness, or validity of the content of the presentations or the medical opinions expressed by individual speakers.

*The information presented herein is not intended to promote or solicit any specific pharmaceutical products, medical devices, or treatment methods.